CanSinoBIO’s inhalation COVID-19 shot in mid-stage trial, says CEO


A brand of China’s vaccine specialist CanSino Biologics Inc is pictured on the corporate’s headquarters in Tianjin, following an outbreak of the coronavirus illness (COVID-19), China August 17, 2020. REUTERS/Thomas Peter/File Picture

An inhalation model of CanSino Biologics’ (6185.HK), COVID-19 vaccine is being examined in a Section II medical trial, Chief Government Yu Xuefeng mentioned late on Wednesday.

Yu made the remark at a panel of the World Well being Discussion board of the Boao Discussion board for Asia.

Our Requirements: The Thomson Reuters Belief Ideas.


Please enter your comment!
Please enter your name here